- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02164201
Post Market Surveillance Study Evaluating BioFoam Surgical Matrix in Cardiovascular Surgery
Post Market Surveillance Study Evaluating the Operative Management of Anastomotic Bleeding by Means of an Adjunctive Application of BioFoam Surgical Matrix in Cardiovascular Surgery
This is a prospective, multicenter, single-arm study designed to collect clinical data to support the safety and effectiveness of BioFoam used as a surgical adjunct to anastomotic hemostasis following cardiovascular surgery.
The overall objective of this clinical study is to collect clinical data supporting the safety and effectiveness of BioFoam used as a surgical adjunct to anastomotic hemostasis following cardiovascular surgery. This study is intended as a post-market surveillance (follow-up) study.
연구 개요
상태
연구 유형
등록 (실제)
연락처 및 위치
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients undergoing cardiac or cardiovascular procedures, including, but not limited to:
Thoracic Aortic Aneurysm Aortic Valve Replacement Type A Aortic Dissection (where BioFoam is limited to the anastomotic site)
설명
Inclusion Criteria:
- Subject is undergoing an elective cardiac or cardiovascular procedure;
- Subject is willing and able to give prior written informed consent for investigation participation; and
- Subject is > 18 years of age.
Intraoperative inclusion criteria include:
• Subject that requires the use of an adjunctive surgical hemostatic agent to the repair site to control generalized oozing following standard repair procedures (such as sutures and staples).
Exclusion Criteria:
• Subject with known hypersensitivity to albumin, bovine products, or glutaraldehyde;
- Subject with active infection (either systemic or in the repair region);
- Subject whose pathology or underlying disease state makes them an unacceptable candidate for a clinical investigation in the opinion of the Investigator;
- Subject diagnosed with a coagulation disorder;
- Subject with abnormal calcium metabolism (e.g., chronic renal failure, hyperparathyroidism);
- Subject whose life expectancy is less than that required for the prescribed follow-up duration;
- Subject who is pregnant, planning on becoming pregnant during the follow-up period, or actively breast-feeding; or
- Subject who is immunocompromised.
Intraoperative exclusion criteria include:
• Any major intraoperative bleeding incidences (i.e., American College of Surgeons Advanced Trauma Life Support Class II, III, or IV Hemorrhage).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Achievement of haemostasis
기간: 3 minutes after application
|
3 minutes after application
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Time to haemostasis
기간: measured through to 10 minutes
|
measured through to 10 minutes
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Bernhard Voss, PD Dr Med, Deutsches Herzzentrum Muenchen
- 수석 연구원: Ottavio Alfieri, Professor, San Raffale Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .